[{"id":"d7c33d28-bc2c-488a-ae44-8439d7424f2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05508373","created_at":"2022-08-19T17:10:11.974Z","updated_at":"2024-07-02T16:36:05.136Z","phase":"Phase 1","brief_title":"A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05508373","lead_sponsor":"Suzhou Kebo Ruijun Biotechnology Co., Ltd","biomarkers":" ENTPD1","pipe":"","alterations":" ","tags":["ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JS019"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2022-08-19"},{"id":"9e2f5cfc-1303-4139-8875-5758a715f3c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05374226","created_at":"2022-05-16T13:53:38.129Z","updated_at":"2024-07-02T16:36:10.410Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05374226","lead_sponsor":"Suzhou Kebo Ruijun Biotechnology Co., Ltd","biomarkers":" ENTPD1","pipe":"","alterations":" ","tags":["ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JS019"],"overall_status":"Recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 12/11/2023","primary_completion_date":" 12/11/2023","study_txt":" Completion: 03/07/2024","study_completion_date":" 03/07/2024","last_update_posted":"2022-05-16"}]